Samyang Biopharm Corporation

Platinum Sponsor

Samyang Group is a multinational conglomerate founded in South Korea in 1924, operating across diverse sectors including Biopharmaceuticals, Food, Chemicals, Packaging, and Cosmetics. Over the past decades, Samyang Biopharm Corporation has built a strong foundation in drug delivery systems, leveraging its expertise in biodegradable polymers and polymeric formulation technology. This dedication has led to the successful commercialization of modified anti-cancer generics and medical devices, earning global recognition for quality and safety.

Currently, our primary focus is on the development of SENS™ (Selectivity Enabling NanoShell), a novel drug delivery platform designed for tissue-selective delivery of nucleic acid therapeutics. SENS™ is uniquely composed of biodegradable polymers and newly discovered ionizable lipids. By adjusting composition and fine-tuning formulation processes, SENS™ enables targeted delivery of mRNA to specific tissues (e.g., spleen, lung, muscle, CNS, liver) while offering superior safety profiles that support repeat dosing.

One of our key innovations, NanoReady, is a proprietary, ready-to-use SENS™ formulation. This pre-made nanoparticle system can be easily combined with mRNA immediately before administration, streamlining process development, reducing time-to-patient, and enabling personalized cancer vaccines.

Through active collaboration with global partners, we are expanding our SENS™ platform across a range of mRNA-based therapeutics, including prophylactic and therapeutic cancer vaccines, protein replacement therapies, gene editing medicines, and more.

We are actively seeking strategic partnerships with drug developers aiming to bring RNA therapies into the clinic. By combining their therapeutic innovations with our validated delivery modalities, we can enable safe and selective targeting, maximize clinical impact, and deliver novel therapies to patients.

website